Management Team

Michael S. Anderson
Chief Executive Officer
Michael S. Anderson was appointed Chief Executive Officer of Flamel Technologies in March 2012. Previously, Anderson was the President and Chief Executive Officer of Éclat Pharmaceuticals, L.L.C., a specialty pharma company located in St. Louis, Missouri. Éclat, which began operation in November 2010, was acquired by Flamel in March of this year. Prior to Eclat, Anderson was at KV Pharmaceutical Company, where he served as President and CEO of its generic business, ETHEX Corporation, and was also the President and CEO of Ther-Rx Corporation, a leader in women’s healthcare. He also was with Schein Pharmaceutical and started his career with A.H. Robins Company.
Steven A. Lisi
Senior Vice President, Business and Corporate Development
Mr. Lisi was appointed Senior Vice President, Business and Corporate Development in June 2012. Previously, he served as partner at Deerfield Management, a leading global healthcare focused hedge fund, between 2007 and 2012. Prior to that, he was founder and managing member/portfolio manager at Panacea Asset Management LLC (New York) between 2005 and 2007, and healthcare portfolio manager at Millenium Partners (New York) between 2002 and 2005. Between 1994 and 2002, he served as analyst in several companies. Mr. Lisi is a graduate of Pepperdine University (Malibu, California).
Phillandas T. Thompson, J.D., M.B.A.
Senior Vice President, General Counsel and Corporate Secretary
Mr. Thompson was appointed Senior Vice President, General Counsel in November 2013. Previously, he served as Vice President, Legal Affairs at West-Ward Pharmaceutical Corp. (2012-2013), Vice President, General Counsel at Paddock Laboratories, Inc. (2010-2012), Vice President, Strategic Business Transactions and Assistant General Counsel at KV Pharmaceutical (2006-2010), Associate General Counsel and Assistant Secretary at Barr Pharmaceutical (2002-2006), and Corporate Associate at White & Case LLP (1998-2002). Mr. Thompson is a member of the New York Bar, the Missouri Bar, and the Minnesota Bar and has several other professional affiliations. Mr. Thompson earned a B.A. from Washington University in St. Louis and is also a graduate of the University of Michigan Law School (Juris Doctor) and the University of Michigan Business School (Master of Business Administration).
Siân Crouzet
Principal Financial Officer
Mrs. Sian Crouzet has been Principal Financial Officer of Flamel Technologies SA since March 2008. She previously worked as Financial Controller France for McCormick & Company Inc. Mrs. Crouzet also worked five years as an external auditor with Ernst and Young (France and UK). She is a UK Chartered Accountant and a graduate of Bradford University (UK).
Jean Chatellier, Ph.D.
Vice President, Alliance Management and Licensing
Dr. Jean Chatellier joined Flamel Technologies in October 2010 as Vice President of Alliance Management & Licensing. He served previously as Director of Business Development at Micromet (now Amgen) and added other business development activities for Crucell (now Johnson & Johnson) and Viropro. He also was the founder and CEO of Avidis (now Imaxio), and was CEO and liquidator of Aptanomics. He obtained a binational Ph.D. in Protein Engineering from the universities of Strasbourg (France) and Montréal (Canada). He also performed post-doctoral research with Sir Allan Fersht and Sir Greg Winter (founder of CAT, now MedImmune/AstraZeneca; and Domantis, now GSK Bio-Pharmaceuticals) at the Center for Protein Engineering of the Medical Research Council, Cambridge UK.
Scott Macke
Vice President, Supply Chain and Operations
Mr. Macke has over 20 years of experience in the pharmaceutical industry with direct involvement specific to both API and drug product development and commercialization. Prior to assuming his current position, he held positions of increasing leadership with Éclat Pharmaceuticals, L.L.C., most recently as the Chief Operating Officer. Éclat, founded in November 2010 and located in St. Louis, Missouri, was acquired by Flamel Technologies in March 2013. Prior to Éclat, he served as Sr. Director of Project Management at KV Pharmaceutical (2007 – 2010) and held various technical and operational positions at Mallinckrodt Pharmaceuticals (1993 – 2007). Mr. Macke holds undergraduate degrees in Biology and Chemistry from Missouri State University and a Master of Business Administration from the John E. Simon School of Business at Maryville University.
David Monteith, Ph.D.
Vice President, Research and Development
Dr. Monteith has over 25 years’ experience working in the pharmaceutical and drug delivery industry, mostly in senior leadership roles. He has worked for several pharmaceutical companies including Syntex, Merck-Lipha, Schering Plough and most recently Merck & Co. Inc.  Dr. Monteith is a graduate in Pharmacy from the University of Strathclyde, Glasgow where he also obtained his PhD from the Department of Pharmaceutics. He later also received a MBA from the University of Warwick, UK.  David has held several positions of increasing responsibility in the industry and has spent the last 14 years in the USA with Schering-Plough and Merck.  David has concentrated most of his career in the areas of drug delivery and pharmaceutical drug product development and he most recently served as Associate Vice President of Pharmaceutical Development for Emerging Markets at Merck.
Christian Kalita
Chief Pharmacist
Mr. Christian Kalita has been Responsible Pharmacist, Director of Quality and Regulatory Affairs of Flamel Technologies SA since 2005. He worked previously at Skye Pharma as Director of Quality for Europe. Mr. Kalita also worked at Merck Lipha and Merck generics for 10 years in different roles as Chief Pharmacist, Head of Quality Control Management and Head of Industrial Affairs.
Severine Martin, E.M.B.A.
Director of Human Resources and Corporate Projects
Mrs Martin joined Flamel Technologies in August 2014. She has over 13 years consulting and Human Resources experience with strong involvement in strategy implementation and change management. She held management consulting positions, most recently with Segeco Consulting. Previously, she worked as Director of Human Resources at Segula Technologies after having held leadership HR roles with large organizations in a variety of sectors. Mrs Martin earned an Executive MBA from HEC in Paris. She is also graduated is Human Resources Management from the Institute of Business Administration of Nancy (France).

Board of Directors

The Honorable Craig R. Stapleton
Former United States Ambassador to France, Senior Advisor to Stone Point Capital, Director of Abercrombie & Fitch Co., former President of Marsh and McLennan Real Estate Advisors of New York, President of the Vaclav Havel Foundation in the United States, member of the Board of Directors of the George W. Bush Library and Foundation and of the National September 11 Memorial and Museum at the World Trade Center
Michael S. Anderson
Chief Executive Officer of Flamel Technologies
Guillaume Cerutti
Chairman and CEO of Sotheby’s France
Francis J.T. Fildes, Ph.D.
Former Senior Vice President: Head of Global Development for AstraZeneca, PLC, Director of ProStrakan Group PLC and Fildes Partners Ltd, and a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry
Christophe Navarre
President and CEO of Moët-Hennessy (the Wine and Spirits division of LVMH), Board Member of the Comité Colbert, Member of the HEINEKEN Supervisory Board and Chairman of the FEVS (Fédération des Exportateurs de Vins et Spiritueux), Officer of the Legion of Honour (France), Commander of the Order of Agricultural Merit (France), Commander of the Order of Leopold II (Belgium) and Officer of the Royal Order of the Crown of Belgium
Ben C. Van Assche
Executive Chairman Armonea, Chairman of the Board of Bone Therapeutis, Member Of The Supervisory Board at Punch Graphix plc, former CEO of Xeikon, former chairman of Essenscia, global assignments in large and mid-size companies such as Cytec, UCB, Alcon and Baxter